These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16240210)

  • 21. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
    Remák E; Brown RE; Yuen C; Robinson A
    Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rabeprazole is latest entrant in proton-pump-inhibitor class.
    Miller JL
    Am J Health Syst Pharm; 1999 Oct; 56(19):1910. PubMed ID: 10554904
    [No Abstract]   [Full Text] [Related]  

  • 23. [Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
    Minushkin ON; Maslovskiĭ LV; Anikina NIu; Shuleshova AG
    Eksp Klin Gastroenterol; 2005; (2):29-35. PubMed ID: 15932152
    [No Abstract]   [Full Text] [Related]  

  • 24. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW; Goh KL; Wong BC
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
    Archimandritis AJ; Nikolopoulou V; Kouklakis G; Paraskevas E; Avgerinos A; Tsianos E; Triantafillidis JK;
    Curr Med Res Opin; 2005 Apr; 21(4):603-10. PubMed ID: 15899110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.
    Nelson WW; Vermeulen LC; Geurkink EA; Ehlert DA; Reichelderfer M
    Arch Intern Med; 2000 Sep; 160(16):2491-6. PubMed ID: 10979061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acid pump inhibitors. The treatment of gastroesophageal reflux.
    Hetzel D
    Aust Fam Physician; 1998 Jun; 27(6):487-91. PubMed ID: 9648315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
    Miner P; Orr W; Filippone J; Jokubaitis L; Sloan S
    Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
    Kahrilas PJ; Miner P; Johanson J; Mao L; Jokubaitis L; Sloan S
    Dig Dis Sci; 2005 Nov; 50(11):2009-18. PubMed ID: 16240208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].
    Vasil'ev IuV; Noskova KK; Zelenikin SA
    Eksp Klin Gastroenterol; 2002; (1):55-60, 190. PubMed ID: 12271586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
    Dtsch Med Wochenschr; 1998 Nov; 123(47 Suppl):1-4. PubMed ID: 9856116
    [No Abstract]   [Full Text] [Related]  

  • 36. [Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment].
    Yang XL; Liu XH; Ke MY; Song ZQ; Yuan YZ; Luo JY; Hou XH
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2404-7. PubMed ID: 20137694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A; Wruble LD; Humphries TJ
    Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.
    Giannini EG; Savarino V; Testa R
    Dig Dis Sci; 2006 Sep; 51(9):1602-6. PubMed ID: 16927149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():30-7. PubMed ID: 15496216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.